Press "Enter" to skip to content

Biocon extends licensing pact with Equillium for itolizumab

Itolizumab, a first-in-class humanized anti-CD6 monoclonal antibody, is developed by Biocon and launched in 2013 in India under the brand name ALZUMAb to treat moderate to severe plaque psoriasis, a skin disease.

Original source: https://health.economictimes.indiatimes.com/news/pharma/biocon-extends-licensing-pact-with-equillium-for-itolizumab/72499886?utm_source=RSS&utm_medium=ETRSS

Also Read:   Pharma company accountant held for sharing its data with rival firm